| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.0047 | 1 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.00068 | 1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.00059 | 1 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.00056 | 1 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0007 | 1 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.00051 | 1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.00035 | 1 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.00023 | 1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00018 | 1 |